The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del (17p).
 
Nitin Jain
Honoraria - Adaptive Biotechnologies; ADC Therapeutics; Novartis; Novimmune; Pfizer; Pharmacyclics; SERVIER
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Pfizer (Inst); Pharmacyclics (Inst); Seagen (Inst); SERVIER (Inst)
 
Philip A. Thompson
No Relationships to Disclose
 
Jan Andreas Burger
Research Funding - Pharmacyclics (Inst)
 
Gautam Borthakur
No Relationships to Disclose
 
Prithviraj Bose
Honoraria - Incyte
Consulting or Advisory Role - Incyte
Research Funding - Celgene
Travel, Accommodations, Expenses - Incyte
 
Zeev Estrov
No Relationships to Disclose
 
Alessandra Ferrajoli
No Relationships to Disclose
 
Varsha Gandhi
Research Funding - Genentech (Inst); Pharmacyclics (Inst)
 
William Plunkett
No Relationships to Disclose
 
Wanda Lopez
No Relationships to Disclose
 
Hagop M. Kantarjian
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst)
 
Susan Mary O'Brien
Honoraria - Abbvie; Alexion Pharmaceuticals; Amgen; Aptose Biosciences; Astellas Pharma; Celgene; Gilead Sciences; GlaxoSmithKline; Janssen; Pfizer; Pharmacyclics; ProNAi; Regeneron; Sunesis Pharmaceuticals; Vaniam Group
Consulting or Advisory Role - Abbvie/Genentech; Alexion Pharmaceuticals; Amgen; Amgen Astellas BioPharma; Aptose Biosciences; Celgene; CLL Global Research Foundation; GlaxoSmithKline; Janssen Oncology; Sunesis Pharmaceuticals; Vaniam Group
Research Funding - Acerta Pharma; Gilead Sciences; Pfizer; Pharmacyclics; ProNAI; Regeneron; TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Janssen; Janssen Oncology; Regeneron
 
Michael J. Keating
No Relationships to Disclose
 
William G. Wierda
Consulting or Advisory Role - Abbvie; Celgene; Emergent BioSolutions; Genentech/Roche; Genzyme; Gilead Sciences; GlaxoSmithKline/Novartis; Merck; Pharmacyclics; Sanofi
Research Funding - Abbvie; Acerta Pharma; Emergent BioSolutions; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Pharmacyclics